FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384029064> ?p ?o ?g. }

• W4384029064 abstract "Abstract Background Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib and niraparib, have been increasingly used in ovarian cancer treatment. However, the real-world safety data of these drugs in Japanese patients and the predictability of treatment interruptions are limited. Methods This retrospective study included 181 patients with ovarian cancer who received olaparib or niraparib at two independent hospitals in Japan between May 2018 and December 2022. Clinical information and blood sampling data were collected. Patient characteristics, treatment history, and hematological data trends were compared, and the predictability of treatment interruptions based on blood sampling data was examined. Results Regarding patient backgrounds, the olaparib group had higher proportions of patients with serous carcinoma, BRCA positivity, homologous recombination deficiency, and those receiving maintenance therapy after recurrence treatment than the niraparib group. Regarding toxicity properties, the most common reasons for discontinuation in the olaparib group were anemia, fatigue, and nausea, while discontinuation was primarily due to thrombocytopenia in the niraparib group. Thrombocytopenia caused by niraparib treatment occurred earlier than anemia caused by olaparib treatment. Patients with a low body mass index or who had undergone several previous treatment regimens were more likely to discontinue treatment due to adverse effects within the first 3 months. Although we analyzed blood collection data, predicting treatment interruptions due to blood toxicity using blood data was challenging. Conclusions In this study, we revealed the characteristics of patients and the timing of interruptions for each drug, highlighting the importance of carefully managing adverse effects, particularly during the early treatment stages." @default.
• W4384029064 created "2023-07-13" @default.
• W4384029064 creator A5015215943 @default.
• W4384029064 creator A5026106569 @default.
• W4384029064 creator A5028439568 @default.
• W4384029064 creator A5057310332 @default.
• W4384029064 creator A5064350256 @default.
• W4384029064 creator A5064908158 @default.
• W4384029064 creator A5075811829 @default.
• W4384029064 creator A5076332969 @default.
• W4384029064 creator A5078859785 @default.
• W4384029064 creator A5079407472 @default.
• W4384029064 creator A5081024848 @default.
• W4384029064 creator A5086951790 @default.
• W4384029064 date "2023-07-12" @default.
• W4384029064 modified "2023-10-18" @default.
• W4384029064 title "Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer" @default.
• W4384029064 cites W2101907683 @default.
• W4384029064 cites W2123696077 @default.
• W4384029064 cites W2160466424 @default.
• W4384029064 cites W2528228811 @default.
• W4384029064 cites W2560688864 @default.
• W4384029064 cites W2737389832 @default.
• W4384029064 cites W2772815803 @default.
• W4384029064 cites W2897430921 @default.
• W4384029064 cites W2900491285 @default.
• W4384029064 cites W2906986535 @default.
• W4384029064 cites W2913253891 @default.
• W4384029064 cites W2935541805 @default.
• W4384029064 cites W2945357020 @default.
• W4384029064 cites W2968394742 @default.
• W4384029064 cites W2972664697 @default.
• W4384029064 cites W2975141952 @default.
• W4384029064 cites W2994977341 @default.
• W4384029064 cites W3028739923 @default.
• W4384029064 cites W3049395940 @default.
• W4384029064 cites W3093287410 @default.
• W4384029064 cites W3113077828 @default.
• W4384029064 cites W3120953566 @default.
• W4384029064 cites W3128646645 @default.
• W4384029064 cites W3156758253 @default.
• W4384029064 doi "https://doi.org/10.21203/rs.3.rs-3129590/v1" @default.
• W4384029064 hasPublicationYear "2023" @default.
• W4384029064 type Work @default.
• W4384029064 citedByCount "0" @default.
• W4384029064 crossrefType "posted-content" @default.
• W4384029064 hasAuthorship W4384029064A5015215943 @default.
• W4384029064 hasAuthorship W4384029064A5026106569 @default.
• W4384029064 hasAuthorship W4384029064A5028439568 @default.
• W4384029064 hasAuthorship W4384029064A5057310332 @default.
• W4384029064 hasAuthorship W4384029064A5064350256 @default.
• W4384029064 hasAuthorship W4384029064A5064908158 @default.
• W4384029064 hasAuthorship W4384029064A5075811829 @default.
• W4384029064 hasAuthorship W4384029064A5076332969 @default.
• W4384029064 hasAuthorship W4384029064A5078859785 @default.
• W4384029064 hasAuthorship W4384029064A5079407472 @default.
• W4384029064 hasAuthorship W4384029064A5081024848 @default.
• W4384029064 hasAuthorship W4384029064A5086951790 @default.
• W4384029064 hasBestOaLocation W43840290641 @default.
• W4384029064 hasConcept C104317684 @default.
• W4384029064 hasConcept C121608353 @default.
• W4384029064 hasConcept C126322002 @default.
• W4384029064 hasConcept C143998085 @default.
• W4384029064 hasConcept C182979987 @default.
• W4384029064 hasConcept C185592680 @default.
• W4384029064 hasConcept C197934379 @default.
• W4384029064 hasConcept C2778248108 @default.
• W4384029064 hasConcept C2778715236 @default.
• W4384029064 hasConcept C2779138821 @default.
• W4384029064 hasConcept C2779962180 @default.
• W4384029064 hasConcept C2780427987 @default.
• W4384029064 hasConcept C55493867 @default.
• W4384029064 hasConcept C71924100 @default.
• W4384029064 hasConcept C82381507 @default.
• W4384029064 hasConceptScore W4384029064C104317684 @default.
• W4384029064 hasConceptScore W4384029064C121608353 @default.
• W4384029064 hasConceptScore W4384029064C126322002 @default.
• W4384029064 hasConceptScore W4384029064C143998085 @default.
• W4384029064 hasConceptScore W4384029064C182979987 @default.
• W4384029064 hasConceptScore W4384029064C185592680 @default.
• W4384029064 hasConceptScore W4384029064C197934379 @default.
• W4384029064 hasConceptScore W4384029064C2778248108 @default.
• W4384029064 hasConceptScore W4384029064C2778715236 @default.
• W4384029064 hasConceptScore W4384029064C2779138821 @default.
• W4384029064 hasConceptScore W4384029064C2779962180 @default.
• W4384029064 hasConceptScore W4384029064C2780427987 @default.
• W4384029064 hasConceptScore W4384029064C55493867 @default.
• W4384029064 hasConceptScore W4384029064C71924100 @default.
• W4384029064 hasConceptScore W4384029064C82381507 @default.
• W4384029064 hasLocation W43840290641 @default.
• W4384029064 hasOpenAccess W4384029064 @default.
• W4384029064 hasPrimaryLocation W43840290641 @default.
• W4384029064 hasRelatedWork W2164296043 @default.
• W4384029064 hasRelatedWork W2489000876 @default.
• W4384029064 hasRelatedWork W2561042858 @default.
• W4384029064 hasRelatedWork W2562267900 @default.
• W4384029064 hasRelatedWork W2755080961 @default.
• W4384029064 hasRelatedWork W2942893873 @default.
• W4384029064 hasRelatedWork W3047344552 @default.
• W4384029064 hasRelatedWork W4224221368 @default.

• next